Key result
This review summarizes the characteristics, reasons for switching, and conversion methods among oral anticoagulants including warfarin, dabigatran, rivaroxaban, and apixaban.
This review summarizes the characteristics, reasons for switching, and methods for conversion between warfarin, dabigatran, rivaroxaban, and apixaban.
Answers are grounded in this paper and cite their sources.
Offers synthesized switching guidance for common OACs; leaves open the need for prospective validation of protocols.
Until about 4 years ago, warfarin was the only oral anticoagulant approved in the United States, and switching between oral anticoagulants has become an option since the emergence of the novel oral anticoagulants dabigatran, rivaroxaban, and apixaban. What are the reasons one may switch between the agents and how is this done? Discussed in this article are the 4 agents approved in the United States, their characteristics, reasons one may switch, and methods for conversion. After a thorough search of original trial data and recent expert review articles, we have summarized the most recent recommendations below and briefly discuss upcoming oral anticoagulants that show promise.
No takes yet. Share an insight, caveat, or question.
Strasser et al. (2014) conducted a review in Indications for oral anticoagulation. Switching between oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban) was evaluated. This review summarizes the characteristics, reasons for switching, and conversion methods among oral anticoagulants including warfarin, dabigatran, rivaroxaban, and apixaban.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: